Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:56:34.687Z.
Calculation as of: 2026-10-06T20:56:34.687Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$406.58M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$405.74M
Price/OCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$404.24M
Price/OCF Ratio
52.50
TTM Avg
165.92
3Y Avg
165.92
5Y Avg
153.23
Market Cap
$411.00M
Price/OCF Ratio
N/A
TTM Avg
78.72
3Y Avg
78.72
5Y Avg
79.60
Market Cap
$411.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $406.58M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | N/A | 6.66 | 6.66 | 6.66 |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | 52.50 | 165.92 | 165.92 | 153.23 |
| Neurogene Inc. (NGNE)vs › | $402.17M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | N/A | 78.72 | 78.72 | 79.60 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $397.99M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
